Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 10, 2014
SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exc...
Feb 5, 2014
SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences at The Waldorf Astoria in New York City: 16th Annual BIO CEO & Investor ConferencePresentation: February 11, 2014, at 9:30 a.m. Eastern Time ...
Jan 6, 2014
SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) at The Westin St. Francis Hotel in San Francisco, Califo...
Nov 27, 2013
SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at The New York Palace Hotel in New York City. ...
Nov 18, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the American Heart Association 2013 Scientific Sessions, November 16-20 in Dallas, Texas.  ...
Nov 13, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 13, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented during ObesityWeekSM 2013, hosted by The Obesity Society and the Americ...
Nov 7, 2013
SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2013. Arena has also rescheduled its conference call and webcast to tomorrow, November 8, 2013, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). "We a...
Nov 7, 2013
SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its ...
Oct 30, 2013
SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and report third quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, November 7, 2013. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time...
Oct 15, 2013
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. will increase its BELVIQ® sales force to approximately 400 representatives by December 2013, doubling the size of the sales force from when BELVIQ became available in June 2013. The expansion of the sales force, which has c...
Sep 23, 2013
SAN DIEGO, Sept. 23, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview, including a BELVIQ® (lorcaserin HCl) CIV launch update, at the NewsMakers in the Biotech Industry conference on Friday, September 27, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pac...
Sep 18, 2013
SAN DIEGO, Sept. 18, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)Barcelona, Spain: September...
Sep 16, 2013
SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided an update on Eisai Inc.'s marketing activities for BELVIQ® (lorcaserin HCl) as the US launch campaign enters its consumer phase. Beginning this month, full-page announcements communicating the availability of BELVIQ are being placed in ma...
Sep 6, 2013
SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 13, 2013, at 1:45 p.m. British Summer Time (5:45 a.m. Pacific Time), at the Bank of America Merrill L...
Aug 28, 2013
SAN DIEGO, Aug. 28, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 ...
= add release to Briefcase